Eli Lilly Reports meta-analysis Data for Inclisiran in ALS

Eli Lilly today announced meta-analysis results for Inclisiran in patients with ALS. The study demonstrated that Inclisiran reduces disease progression risk by over 40% compared to standard of care or placebo. These results provide important insights into the treatment of ALS and support the continued development of Inclisiran in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Inclisiran was consistent with previous observations, with no new safety signals identified.